Biological Therapies Targeting the Type 2 Inflammatory Pathway in Severe Asthma (Review)

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2021 Oct 4

PMID 34603531

Citations 10

Authors

Ariadna Petronela Fildan

Ruxandra-Mioara Rajnoveanu

Roxana Cirjaliu

Ionela Pohrib

Emanuela Tudorache

Adrian Cosmin Ilie

Cristian Oancea

Doina Tofolean

Affiliations

Soon will be listed here.

Abstract

Asthma is a variable chronic respiratory disease characterized by airway inflammation and hyperresponsiveness, bronchoconstriction, and mucus hypersecretion. While most patients with asthma achieve good control of the disease, 5-10% experience severe symptoms and recurrent exacerbation despite the maximal offered therapy with inhaled corticosteroids and long acting bronchodilators. In previous years, novel biological therapies have become available, and various asthma phenotypes that are characterized by specific biomarkers have been identified. Currently approved biological agents target inflammatory molecules of the type 2 inflammatory pathway, and are effective at decreasing the frequency of asthma attacks, controlling symptoms and decreasing use of systemic steroids. The present study reviewed the effectiveness and safety profile of the currently approved biological drugs and provided an overview of the assessment of patients with severe asthma who are potentially suitable for biological therapy, in order to help clinicians to select the most appropriate biological agent.

Citing Articles

Tailoring Biologic Therapies for Pediatric Severe Asthma: A Comprehensive Approach.

Chaverri Reparaz C, Lacalle Fabo E, Erroz Ferrer M, Gimeno-Castillo M, Castro-Garrido I, Ibarzabal-Arregi M Children (Basel). 2025; 12(2).

PMID: 40003242 PMC: 11853801. DOI: 10.3390/children12020140.

Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: A step towards clinical remission.

Al-Ahmad M, Ali A, Talat W, Dawood H, Imam O World Allergy Organ J. 2025; 18(2):101024.

PMID: 39902112 PMC: 11787525. DOI: 10.1016/j.waojou.2024.101024.

The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases.

Shi T, Wu S, Chen R, Xie Y, Yin G, He C BMC Pulm Med. 2024; 24(1):607.

PMID: 39681861 PMC: 11650844. DOI: 10.1186/s12890-024-03414-x.

Biologics and airway remodeling in asthma: early, late, and potential preventive effects.

Varricchi G, Poto R, Lommatzsch M, Brusselle G, Braido F, Virchow J Allergy. 2024; 80(2):408-422.

PMID: 39520155 PMC: 11804314. DOI: 10.1111/all.16382.

Effect of Dupilumab on Radiological Remission in Patients with Chronic Rhinosinusitis with Nasal Polyp: A One Step Forward Toward Clinical Remission.

Al-Ahmad M, Ali A, Dawood H, Beshreda G J Asthma Allergy. 2024; 17:1027-1040.

PMID: 39464420 PMC: 11505379. DOI: 10.2147/JAA.S478040.

References

Busse W . Biological treatments for severe asthma: where do we stand?. Curr Opin Allergy Clin Immunol. 2018; 18(6):509-518. DOI: 10.1097/ACI.0000000000000487. View

Pham T, Damera G, Newbold P, Ranade K . Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016; 111:21-9. DOI: 10.1016/j.rmed.2016.01.003. View

King G, James A, Harkness L, Wark P . Pathophysiology of severe asthma: We've only just started. Respirology. 2018; 23(3):262-271. DOI: 10.1111/resp.13251. View

Ultsch M, Bevers J, Nakamura G, Vandlen R, Kelley R, Wu L . Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013; 425(8):1330-9. DOI: 10.1016/j.jmb.2013.01.024. View

Eger K, Bel E . The emergence of new biologics for severe asthma. Curr Opin Pharmacol. 2019; 46:108-115. DOI: 10.1016/j.coph.2019.05.005. View

McGregor M, Krings J, Nair P, Castro M . Role of Biologics in Asthma. Am J Respir Crit Care Med. 2018; 199(4):433-445. PMC: 6835092. DOI: 10.1164/rccm.201810-1944CI. View

Brightling C, Chanez P, Leigh R, OByrne P, Korn S, She D . Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015; 3(9):692-701. DOI: 10.1016/S2213-2600(15)00197-6. View

Humbert M, Taille C, Mala L, Le Gros V, Just J, Molimard M . Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018; 51(5). PMC: 6383600. DOI: 10.1183/13993003.02523-2017. View

Haldar P, Brightling C, Singapuri A, Hargadon B, Gupta S, Monteiro W . Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014; 133(3):921-3. DOI: 10.1016/j.jaci.2013.11.026. View

10.

Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui M, Lindner L . Matching-adjusted indirect comparison of benralizumab interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018; 52(5). PMC: 6277255. DOI: 10.1183/13993003.01393-2018. View

11.

Mavissakalian M, Brady S . The Current State of Biologic Therapies for Treatment of Refractory Asthma. Clin Rev Allergy Immunol. 2020; 59(2):195-207. DOI: 10.1007/s12016-020-08776-8. View

12.

Edris A, De Feyter S, Maes T, Joos G, Lahousse L . Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019; 20(1):179. PMC: 6688359. DOI: 10.1186/s12931-019-1138-3. View

13.

Perez de Llano L, Cosio B, Domingo C, Urrutia I, Bobolea I, Valero A . Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol Pract. 2019; 7(7):2277-2283.e2. DOI: 10.1016/j.jaip.2019.01.017. View

14.

Corren J, Castro M, Ford L, Bernstein J, Jayawardena S, Maroni J . Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol. 2019; 123(2):222-224.e1. DOI: 10.1016/j.anai.2019.04.028. View

15.

Wechsler M, Colice G, Griffiths J, Almqvist G, Skarby T, Piechowiak T . SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020; 21(1):264. PMC: 7550846. DOI: 10.1186/s12931-020-01503-z. View

16.

Chang Y, Kim H, Albacker L, Baumgarth N, McKenzie A, Smith D . Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011; 12(7):631-8. PMC: 3417123. DOI: 10.1038/ni.2045. View

17.

De Ferrari L, Chiappori A, Bagnasco D, Riccio A, Passalacqua G, Canonica G . Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. Expert Rev Respir Med. 2015; 10(1):29-38. DOI: 10.1586/17476348.2016.1111763. View

18.

Munteanu L, Fildan A, Tudorache E, Fira-Mladinescu O, Frandes M, Timar B . Inhaler technique errors in Romanian patients with asthma - a multicenter study. Patient Prefer Adherence. 2019; 13:1401-1414. PMC: 6707372. DOI: 10.2147/PPA.S209717. View

19.

Murphy K, Jacobs J, Bjermer L, Fahrenholz J, Shalit Y, Garin M . Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017; 5(6):1572-1581.e3. DOI: 10.1016/j.jaip.2017.08.024. View

20.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View